BIO-RAD LABORATORIES, INC. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Bio-Rad reported Q3 2026 net sales of $656.4M (flat YoY, +0.7% currency-neutral), with GAAP operating loss of $49.7M driven by $77.2M restructuring charges and $49.8M intangible impairment. A $588.2M gain from fair-value increase in Sartorius AG investment yielded GAAP net income of $458.6M ($17.02 diluted EPS), masking weak operating performance. Non-GAAP operating income was $83.7M (12.8% margin, +100 bps YoY). For full-year 2026, management narrowed guidance to -3.0% to +0.5% currency-neutral revenue decline and 10-12% non-GAAP operating margin; free cash flow guidance set at $290-340M.
Why this rating
Core business flat/declining; GAAP net income inflated by non-recurring Sartorius valuation gain. Restructuring and impairment signal operational challenges, partially offset by margin expansion. Modest relative to $6.2B market cap; not transformational but indicative of ongoing softness.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.